Recursion Pharmaceuticals (RXRX) said Wednesday that it has completed its business combination with Exscientia (EXAI) and Exscientia is now a wholly owned unit of Recursion.
Exscientia's American depositary shares have stopped trading and will be delisted from Nasdaq, according to Recursion.
The combined company has received about $450 million in upfront and milestone payments from partners and has more than 10 partnered programs in areas such as oncology and immunology, Recursion added.
The deal was first announced in August.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。